QT dispersion in patients with systemic lupus erythematosus: the impact of disease activity

BMC Cardiovascular Disorders

Lida Liaghat²  Gholam reza Rezaian²  Yadollah Mahmoody²  Mohammad Ghahartars²  Mohammad ali Nazarinia¹  Javad Kojuri³ 

[1] Internal Medicine Department, Rheumatology Group, Shiraz University of Medical Sciences, Shiraz, Iran;Cardiology Department, Shiraz University of Medical Sciences, Shiraz, Iran;Medical education, Cardiologist, Interventionis,t Cardiology Department, Namazi Hospital, Zand St., Shiraz, Iran

关键词: QT dispersion;    Disease activity score;    SLE;   

Others  :  1085285
DOI  :  10.1186/1471-2261-12-11

 received in 2011-10-26, accepted in 2012-02-27,  发布年份 2012

【 摘 要 】

Background

Patients with systemic lupus erythematosus (SLE) have increased cardiovascular morbidity and mortality. Although autopsy studies have documented that the heart is affected in most SLE patients, clinical manifestations occur in less than 10%. QT dispersion is a new parameter that can be used to assess homogeneity of cardiac repolarization and autonomic function. We compared the increase in QT dispersion in SLE patients with high disease activity and mild or moderate disease activity.

Methods and Results

One hundred twenty-four patients with SLE were enrolled in the study. Complete history and physical exam, ECG, echocardiography, exercise test and SLE disease activity index (SLEDAI) were recorded. Twenty patients were excluded on the basis of our exclusion criteria. The patients were divided to two groups based on SLEDAI: 54 in the high-score group (SLEDAI > 10) and 50 in the low-score group (SLEDAI < 10).

QT dispersion was significantly higher in high-score group (58.31 ± 18.66 vs. 47.90 ± 17.41 respectively; P < 0.004). QT dispersion was not significantly higher in patients who had received hydroxychloroquine (54.17 ± 19.36 vs. 50.82 ± 15.96, P = 0.45) or corticosteroids (53.58 ± 19.16 vs. 50.40 + 11.59, P = 0.47). There was a statistically significant correlation between abnormal echocardiographic findings (abnormalities of pericardial effusion, pericarditis, pulmonary hypertension and Libman-Sacks endocarditis) and SLEADI (P < 0.004).

Conclusions

QT dispersion can be a useful, simple noninvasive method for the early detection of cardiac involvement in SLE patients with active disease. Concerning high chance of cardiac involvement, cardiovascular evaluation for every SLE patient with a SLEDAI higher than 10 may be recommended.

Trial registration

Clinicaltrial.gov registration NCT01031797

【 授权许可】

   
2012 Kojuri et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Manzi S, Meilahn EN, Rairia JE, et al.: Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol 1997, 145:408-415.
• [2]Ward MM: Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999, 42:338-346.
• [3]Ward MM, Pyun E, Studenski S: Causes of death in systemic lupus erythematosus: Long-term follow-up of an inception cohort. Arthtitis Rheum 1995, 38:1492-1499.
• [4]Abu-Shakra M, Urowitz MB, Gladman DD, Gough J: Mortality studies in systemic lupus erythematosus: results from a single center. I: causes of death. J Rheumatol 1995, 22:1259-1264.
• [5]Jacobsen S, Petersen J, Ulman S, et al.: Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus. Scand J Rheumatol 1999, 28:75-80.
• [6]Schattner A: The cardiovascular burden of lupus. Arch Intern Med 2003, 163:1507-1509.
• [7]Mandell BF: Cardiovascular involvement in systemic lupus erythematosus. Semin Arthritis Rheum 1987, 17:126-141.
• [8]Moder KG, Miller TD, Tazelaar HD: Cardiac involvement in systemic lupus erythematosus. Mayo Clinic Proc 1999, 74:275-284.
• [9]Hejtmancik MR, Wright JC, Quint R, Jennings FL: The cardiovascular manifestations of systemic lupus erythematosus. Am Heart J 1964, 68:119-130.
• [10]Dekker JM, Schouten EG, Klootwijk P, Pool J, Krombout D: Association between QT interval and coronary heart disease in middle-aged and elderly men: the Zutphen study. Circulation 1994, 90:779-785.
• [11]Elming H, Holm E, Jun L, et al.: The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Dansig citizens. Eur Heart J 1998, 19:1391-1400.
• [12]de Bruyne MC, Hoes AW, Kors JA, Hofman A, van Bemmel JH, Grobbee DE: Prolonged QT interval predicts cardiac and all-cause mortality in the elderly. The Rotterdam study. Eur Heart J 1999, 20:278-284.
• [13]Okin PM, Devereux RB, Howard BV, et al.: Assessment of QT interval and QT dispersion for prediction of all-cause and cardiovascular mortality in American Indians. The strong heart study. Circulation 2000, 101:61-66.
• [14]Dekker JM, Crow RS, Hannan PJ, Schouten EG, Folsom AR: Heart rate corrected QT interval prolongation predicts risk of coronary heart disease in black and with middle-aged men and women. The ARIC study. J Am Coll Cardiol 2004, 43:565-571.
• [15]Kautzner J, Malik M: QT interval dispersion and its clinical utility. PACE 1997, 20:2625-2640.
• [16]Zabel M, Portnoy S, Franz MR: Electrocardiographic indexes of dispersion of ventricular repolarization; an isolated heart validation study. J Am Coll Cardiol 1995, 25:746.
• [17]Yildirir A, Aksoyek S, Calguneri M, et al.: QT dispersion as a predictor of arrhythmic events in patients with ankylosing spondylitis. Rheumatology (Oxford) 2000, 39(8):875-879.
• [18]Pirildar T, Sekuri C, Uyuk O, Kemal Tezcan U: QT dispersion in rheumatoid arthritis patients with and without Sjogren's syndrome. Clin Rheumatol 2003, 22:225-228.
• [19]Cindas A, Gokce-Kutsal Y, Tokgozoglu L, Karanfil A: QT dispersion and cardiac involvement in patients with rheumatoid arthritis. Scand J Rheumatol 2002, 31(1):22-26.
• [20]Yavuz B, Atalar E, Karadag O, Tulumen E, Ozer N, et al.: QT dispersion increases in patients with Systemic lupus erythematosus. Clin Rheumatol 2007, 26:376-379.
• [21]Gladman DD, Ibanez D, Urowitz MB: Systemic lupus erythematosus disease activity index. J Rheumatol 2002, 29(2):288-291.
• [22]Bridget G, Marta M, Carolin G: Assessment of patients with systemic lupus erythematosus and use of lupus disease activity index. Best Pract Res Clin Rheumatol 2005, 19(5):685-708.
• [23]Tan EM, Cohen AS, Fries JF, et al.: The revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277.
• [24]Day CP, McComb JM, Campbell RWF: QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J 1990, 63:342-344.
• [25]Mark M, Camm AJ: Mystery of QT interval dispersion. Am J Cardiol 1997, 79:785-787.
• [26]Zabel M, Woosly RL, Franz MR: Is dispersion of ventricular repolarization rate dependent? PACE 1997, 20(1):2405-2411.
• [27]Perkiomaki JS, Koistien J, Yli-Mary S, Huikuri HV: Dispersion of QT interval in patients with and without susceptibility to ventricular tachyarrhythmias after previous myocardial infarction. J Am Coll Cardiol 1995, 26:174-179.
• [28]Statters DJ, Malik M, Ward DE, Camma AJ: QT dispersion: problems of methodology and clinical significance. J Cardiovasc Electrophysiol 1994, 5:672-685.
• [29]Glancy JM, Garrat CJ, Wood KI, de Bono DP: QT dispersion and mortality after myocardial infarction. Lancet 1995, 345:945-948.
• [30]Tieleman RG, Crijns HJ, Wiesfeld AC, Posma J, Hamer HM, Lie KI: Increased dispersion of refractoriness in the absence of QT prolongation in patients with mitral valve prolapse and ventricular arrhythmias. Br Heart J 1995, 73:37-40.
• [31]Barr CS, Naas A, Freeman M, Lang CC, Struthers AD: QT dispersion sudden unexpected death in chronic heart failure. Lancet 1994, 343:327-329.
• [32]Sgreccia A, Morelli S, Ferrante L, et al.: QT interval and QT dispersion in systemic sclerosis (scleroderma). J Int Med 1998, 243:127-132.
• [33]Schillaci O, Lagana B, Danieli R, et al.: Technetium-99 m sestamibi single-photon emission tomography detects subclinical myocardial perfusion abnormalities in patients with systemic lupus erythematosus. Eur J Nucl Med 1999, 26(7):713-717.
• [34]Lin Cc, Ding HJ, Chen YW, Wang JJ, Ho ST, Kao A: usefulness of technetium-99 m sestamibi myocardial perfusion SPECT in detection of cardiovascular involvement in patients with systemic lupus erythematosus or systemic sclerosis. Int J Cardiol 2003, 92:157-161.
• [35]Sun SS, Shiau YC, Tsai SC, Lin CC, Kao A, Lee CC: The role of technetium-99 m sestamibi myocardial perfusion single-photon emission computed tomography (SPECT) in the detection of cardiovascular involvement in systemic lupus erythematosus patients with non-specific chest complaints. Rheumatology 2001, 40:1106-1111.